GIANT BIOGENE2367.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, GIANT BIOGENE (2367.HK) trades at a P/E of 12.50x, P/B of 2.22x, P/S of 3.93x, and a dividend yield of 6.14%.
Longitudinal percentile comparison: P/E sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 35th percentile within its industry and the 56th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 7.48%, ranking at the 100th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 0.0 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 7.48% total shareholder yield, 6.14% is paid out as dividends and roughly 1.34% is implied to come from buybacks — both channels are meaningfully in play. GIANT BIOGENE operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2367 · SEHK: 2367 · 2367
Want the full picture on whether GIANT BIOGENE (2367.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 12.50 | ||||||
| P/B (MRQ) | 2.22 | ||||||
| P/S (TTM) | 3.93 | ||||||
| Dividend Yield | 6.14% | ||||||
| Buyback + Div Yield | 7.48% |